Real world experience of palbociclib in hormone receptor-positive metastatic breast cancer.

被引：3
|
作者：
Malik, Faizan
Ali, Naveed
Jafri, Syed Imran Mustafa
Sundermeyer, Mark L.
Seidman, Michael Jeffrey
Fidler, Christian Joseph
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e18094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18094
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Palbociclib for hormone receptor-positive breast cancer
    Harding, Emilia
    LANCET ONCOLOGY, 2015, 16 (07): : E318 - E318
  • [2] Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer
    Wilkie, Jonathan
    Schickli, M. Alexandra
    Berger, Michael J.
    Lustberg, Maryam
    Reinbolt, Raquel
    Noonan, Anne
    Ramaswamy, Bhuvaneswari
    Sardesai, Sagar
    VanDeusen, Jeffrey
    Wesolowski, Robert
    Williams, Nicole
    Stover, Daniel G.
    Li, Junan
    Vargo, Craig A.
    CLINICAL BREAST CANCER, 2020, 20 (01) : 33 - 40
  • [3] Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
    Yang, Y.
    Sun, C.
    Huang, X.
    Zeng, T.
    Hua, Y.
    Yang, F.
    Li, W.
    Yin, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1264 - S1264
  • [4] Palbociclib in hormone positive metastatic breast cancer: A real world multicenter Indian experience.
    Rauthan, Amit
    Patil, Poonam
    Somashekhar, S. P.
    Jacob, Linu Abraham
    Lokanatha, D.
    Kumar, Kishore
    Keechilat, Pavithran
    Vijayakumar, D. K.
    Patil, Shekar
    Shashidhara, H. P.
    Zaveri, Shabber
    Yashas, Nitin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
    Alaklabi, Sabah
    Roy, Arya Mariam
    Attwood, Kristopher
    George, Anthony
    O'Connor, Tracey
    Early, Amy
    Levine, Ellis G.
    Gandhi, Shipra
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ahrong Ham
    Min Hwan Kim
    Gun Min Kim
    Jee Hung Kim
    Jee Ye Kim
    Hyung Seok Park
    Seho Park
    Young Up Cho
    Byeong Woo Park
    Seung Il Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2020, 183 : 107 - 116
  • [7] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ham, Ahrong
    Kim, Min Hwan
    Kim, Gun Min
    Kim, Jee Hung
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Cho, Young Up
    Park, Byeong Woo
    Kim, Seung Il
    Sohn, Joohyuk
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 107 - 116
  • [8] Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ahrong Ham
    Min Hwan Kim
    Gun Min Kim
    Jee Hung Kim
    Jee Ye Kim
    Hyung Seok Park
    Seho Park
    Young Up Cho
    Byeong Woo Park
    Seung Il Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2020, 183 : 493 - 493
  • [9] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
    Pauline du Rusquec
    Clément Palpacuer
    Loic Campion
    Anne Patsouris
    Paule Augereau
    Carole Gourmelon
    Marie Robert
    Laurence Dumas
    Folliard Caroline
    Mario Campone
    Jean-Sébastien Frenel
    Breast Cancer Research and Treatment, 2018, 168 : 559 - 566
  • [10] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
    du Rusquec, Pauline
    Palpacuer, Clement
    Campion, Loic
    Patsouris, Anne
    Augereau, Paule
    Gourmelon, Carole
    Robert, Marie
    Dumas, Laurence
    Caroline, Folliard
    Campone, Mario
    Frenel, Jean-Sebastien
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 559 - 566
12345